News | May 05, 2009

Breast Surgeons Meeting Discusses Laser Treatment for Benign Breast Tumors

May 5, 2009 - A panel at the recent meeting of the 10th Annual Meeting of the American Society of Breast Surgeons, held April 22-26 in San Diego, included discussion of the advantages of a new laser treatment for fibroadenomas, using the Novilase Breast Therapy to offer a minimally invasive alternative to lumpectomy.

Novilase Breast Therapy uses direct laser therapy to treat fibroadenomas. The system aims to treat these noncancerous tumors while minimizing risks and maintaining the breast’s natural shape and feel.

Among the panelists was Kambiz Dowlat, M.D., a professor of surgery at the Rush University Medical Center in Chicago. Dr. Dowlat pioneered laser treatment of small breast tumors. The procedure he developed is now performed with the Novilase Interstitial Laser Therapy device.

“With the X-ray guided laser technology we have today, lumpectomy is overkill,” said Dr. Dowlat. “Lumpectomy creates a significant scar and can deform the breast when you take the tumor out. Fibroadenomas can be precisely ablated with a laser, giving a superior result and less medical risk than lumpectomy. This is a great boon for patients because they can have their benign tumors treated without significant consequences for their health or appearance.”
Dr. Dowlat noted that breast health is moving toward treatments, such as Novilase, that are less invasive and have fewer side effects.
Tumors are now being detected at earlier stages when they are smaller. Because laser therapy is less intimidating for most women, the procedure provides them with a third treatment option besides surgery and a “watch and wait” approach, which may encourage them to take advantage of early detection.

Dr. Dowlat’s remarks emphasized several benefits of laser treatment over lumpectomy surgery, the traditional approach to treating fibroadenomas:
- Minimal scarring. Because no incision is made, laser treatment generally leaves only minimal scars.
- Natural shape and feel maintained. There is typically no “dimpling” with laser treatment because unlike a lumpectomy, the procedure does not remove tissue. In addition, the body’s natural healing process repairs the tumor site and restores the breast’s natural feel.
• Less risk of adverse reaction. Laser treatment can be performed using local anesthetic. A lumpectomy often requires IV sedation or a general anesthetic, which can be riskier.
• Less infection risk. The procedure involves the insertion of a laser probe and a thermal probe through two 1/8- inch skin nicks. The small size of the nicks keeps the infection risk extremely low. In contrast, a lumpectomy uses a 2 inch-to-3 inch incision, which creates a greater risk of infection.
• Faster recovery. A patient can resume normal activity within a few hours of the procedure. Recovery from a lumpectomy can take several days.
About 10 percent of all women will experience fibroadenomas during their lifetime. Although not cancerous, fibroadenomas can cause physical discomfort and also anxiety because of the association of lumps with breast cancer. Thus, after consultation with their physicians, many women with this condition request that their fibroadenomas be removed.

While Novilase uses direct laser therapy to treat fibroadenomas, laser ablation has been successfully used to treat benign prostate tumors. Novilase also uses the same image guidance for breast biopsy.

For more information: www.novianhealth.com

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...